Skip to content

Persistent Atrial Fibrillation Ablation Trial

Persistent Atrial Fibrillation Ablation Trial

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01891825
Acronym
PAAT
Enrollment
50
Registered
2013-07-03
Start date
2014-09-30
Completion date
2016-09-30
Last updated
2014-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial fibrillation, Persistent atrial fibrillation, Atrial fibrillation ablation

Brief summary

Persistent atrial fibrillation (AF) is a common and distressing condition, that can cause significant symptoms. AF ablation is a recognised technique to treat persistent AF, but can be technically difficult. This study compares percutaneous ablation to thoracoscopic surgical AF ablation.

Interventions

PROCEDURESurgical AF ablation

Minimally invasive thoracoscopic surgical ablation of atrial fibrillation

PROCEDUREPercutaneous AF ablation

Percutaneous catheter ablation of atrial fibrillation

Sponsors

Neil Sulke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptomatic persistent or long-standing AF suitable for AF ablation. * Age over 18 years old. * Informed consent to participate in this study.

Exclusion criteria

* Pre-existing ILRs or permanent pacemakers that do not allow for continuous monitoring for AF occurrence, or are not MRI-safe. * Unable to undergo general anaesthesia for AF ablation. * Previous cardiac surgery, such as coronary artery bypass grafting or valvular surgery. * Scheduled for elective cardiac surgery, such as coronary artery bypass grafting or valvular surgery. * Previous thoracic surgery. * Participation in a conflicting study. * Potential participants who are mentally incapacitated and cannot consent or comply with follow-up * Pregnancy * Other cardiac rhythm disorders

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of persistent AF by 12 months after ablation12 monthsMean time to recurrence of persistent AF after ablation

Secondary

MeasureTime frameDescription
Time to first episode of symptomatic AF after ablation12 monthsTime to first episode of symptomatic AF after ablation
Time to first episode of any AF after ablation12 monthsAs detected by ILR
Total number of AF episodes after AF ablation12 monthsAs detected by ILR, outside blanking period
Total number of AF episodes lasting greater than 6 minutes after AF ablation12 monthsAs detected by ILR, outside blanking period
New MRI-detected subclinical cerebral embolic events3 months
Change in AF burden after AF ablation12 monthsDetected by ILR

Other

MeasureTime frame
Change in echocardiographic left atrial dimensions and function after AF ablation12 months
Change in cognitive function as assessed by the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) instruments12 months
Change in exercise capacity assessed by cardiopulmonary exercise testing (CPET) after AF ablation12 months
Quality of life changes after AF ablation12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026